Tealwood Asset Management Inc. has significantly increased its investment in Corcept Therapeutics Incorporated (NASDAQ:CORT), raising its stake by 58.0% during the third quarter of 2023. According to the firm’s latest Form 13F filing with the Securities and Exchange Commission (SEC), Tealwood now holds 31,156 shares of the biotechnology company, having acquired an additional 11,433 shares during this period. The total value of Tealwood’s investment in Corcept Therapeutics is estimated at $2,589,000.
Other institutional investors have also made notable adjustments to their positions in Corcept Therapeutics. Golden State Wealth Management LLC purchased a new stake worth approximately $28,000 in the second quarter. Similarly, Huntington National Bank increased its holdings by 54.0%, owning 479 shares valued at $35,000 after acquiring an additional 168 shares. Employees Retirement System of Texas and USA Financial Formulas also entered the market, investing $52,000 and $56,000 respectively. Farther Finance Advisors LLC saw the most significant increase, raising its stake by 277.6%, resulting in a total of 910 shares valued at $67,000. Institutional investors and hedge funds collectively own 93.61% of Corcept’s stock.
Corcept Therapeutics Stock Performance
On December 1, 2023, shares of Corcept Therapeutics opened at $82.65. The stock has experienced a 52-week low of $49.00 and a high of $117.33. Financial ratios indicate a solid balance sheet, with a debt-to-equity ratio of 0.01, a quick ratio of 3.07, and a current ratio of 3.14. The company’s market capitalization stands at $8.69 billion, with a price-to-earnings (PE) ratio of 93.92 and a beta of 0.20.
Insider trading activity has also been notable. CEO Joseph K. Belanoff sold 40,000 shares on December 1, realizing a total of $3,190,800 from the sale. Following this transaction, he retains 2,701,370 shares valued at around $215,488,284.90, reflecting a 1.46% decrease in his ownership. Another insider, Sean Maduck, sold 20,000 shares on the same day for $1,590,400, leaving him with 7,904 shares valued at $628,526.08, representing a significant 71.67% decrease in his position. Over the last three months, insiders have collectively sold 261,700 shares valued at $21,002,348. Currently, insiders own 20.80% of the company’s stock.
Analyst Ratings and Future Outlook
Recent analyst reviews reflect cautious optimism for Corcept Therapeutics. Canaccord Genuity Group reaffirmed a “buy” rating with a price target of $140.00, while UBS Group initiated coverage with a “neutral” rating and a target of $95.00. Wolfe Research has also begun coverage with a “peer perform” rating. Zacks Research upgraded the stock from a “strong sell” to a “hold” rating, and Weiss Ratings maintained a “hold (c)” rating. Currently, four analysts have rated Corcept with a “buy” rating, while four others have issued a “hold” rating, resulting in an average rating of “Moderate Buy” with a projected price target of $127.20.
Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies that modulate the effects of cortisol, a hormone linked to various serious conditions. Its flagship product, **Korlym (mifepristone)**, is approved in the United States for treating hyperglycemia secondary to Cushing’s syndrome in patients who cannot undergo surgery.
For those interested in tracking hedge fund activities related to Corcept Therapeutics, up-to-date information can be found through various financial news platforms.
